MX2020000352A - Marcador radioactivo de modo dual y terapeuticos. - Google Patents
Marcador radioactivo de modo dual y terapeuticos.Info
- Publication number
- MX2020000352A MX2020000352A MX2020000352A MX2020000352A MX2020000352A MX 2020000352 A MX2020000352 A MX 2020000352A MX 2020000352 A MX2020000352 A MX 2020000352A MX 2020000352 A MX2020000352 A MX 2020000352A MX 2020000352 A MX2020000352 A MX 2020000352A
- Authority
- MX
- Mexico
- Prior art keywords
- radiotracer
- therapeutics
- dual mode
- sifa
- silicon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17183795 | 2017-07-28 | ||
| PCT/EP2018/070533 WO2019020831A1 (en) | 2017-07-28 | 2018-07-30 | AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000352A true MX2020000352A (es) | 2020-08-17 |
Family
ID=59501286
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000352A MX2020000352A (es) | 2017-07-28 | 2018-07-30 | Marcador radioactivo de modo dual y terapeuticos. |
| MX2023007914A MX2023007914A (es) | 2017-07-28 | 2020-01-10 | Marcador radioactivo de modo dual y terapeuticos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007914A MX2023007914A (es) | 2017-07-28 | 2020-01-10 | Marcador radioactivo de modo dual y terapeuticos. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11413360B2 (enExample) |
| EP (3) | EP3658194B1 (enExample) |
| JP (2) | JP7059372B2 (enExample) |
| KR (2) | KR102752620B1 (enExample) |
| CN (1) | CN111132700B (enExample) |
| AU (2) | AU2018308699B2 (enExample) |
| BR (1) | BR112020001785A2 (enExample) |
| CA (1) | CA3071315A1 (enExample) |
| DK (1) | DK3658194T3 (enExample) |
| EA (1) | EA202090370A1 (enExample) |
| ES (1) | ES3011272T3 (enExample) |
| FI (1) | FI3658194T3 (enExample) |
| HU (1) | HUE070098T2 (enExample) |
| IL (2) | IL318092A (enExample) |
| MX (2) | MX2020000352A (enExample) |
| PL (1) | PL3658194T3 (enExample) |
| PT (1) | PT3658194T (enExample) |
| SG (1) | SG11202000725WA (enExample) |
| WO (1) | WO2019020831A1 (enExample) |
| ZA (1) | ZA202000467B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11413360B2 (en) * | 2017-07-28 | 2022-08-16 | Technische Universität München | Dual mode radiotracer and—therapeutics |
| AU2020213678B2 (en) | 2019-01-30 | 2024-05-30 | Technische Universität München | PSMA binding dual mode radiotracer and therapeutic |
| WO2020157128A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof |
| IL303420A (en) * | 2019-01-30 | 2023-08-01 | Univ Muenchen Tech | Diagnostic imaging materials for cancer |
| CN112168978B (zh) * | 2019-07-03 | 2022-01-11 | 北京大学 | 一种抗体偶联药物及其药物组合物与应用 |
| CA3155519A1 (en) * | 2019-10-29 | 2021-05-06 | Steve Shih-Lin Huang | Psma-targeting imaging agents |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| GB202005282D0 (en) * | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| EP4185336A1 (en) | 2020-07-23 | 2023-05-31 | Technische Universität München | Silicon-containing ligand compounds |
| WO2022051684A1 (en) | 2020-09-03 | 2022-03-10 | Curium Us Llc | Radiolabeling and formulation for scale up of 64cu-dotatate |
| EP4023250A1 (en) | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| JP2024507343A (ja) * | 2021-02-15 | 2024-02-19 | テクニシェ ユニバーシタット ミュンヘン | デュアルモード放射性トレーサーおよびその療法 |
| IL308414A (en) * | 2021-05-14 | 2024-01-01 | Technische Universit?T M?Nchen | Radiopharmaceutical somatostatin receptor ligands and their precursors |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| WO2023012282A1 (en) * | 2021-08-05 | 2023-02-09 | Technische Universität München | Ligand compounds comprising a chelating group as a bridging group |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| GB202207372D0 (en) | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
| CA3257852A1 (en) | 2022-07-29 | 2024-02-01 | Technische Universitat Munchen | Silicon Fluoride Accepting Groups for Radiopharmaceutical Products |
| WO2024054226A1 (en) * | 2022-09-06 | 2024-03-14 | Hoang Ba Xuan | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment |
| JP2025532619A (ja) * | 2022-09-20 | 2025-10-01 | テクニシェ ユニバーシタット ミュンヘン | イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン２受容体結合分子 |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| JP2025539087A (ja) * | 2022-11-14 | 2025-12-03 | アクティス オンコロジー， インコーポレイテッド | 腎臓におけるミニタンパク質の減少された保持 |
| WO2025072791A2 (en) | 2023-09-29 | 2025-04-03 | Aktis Oncology, Inc. | Miniproteins, conjugates & uses thereof |
| GB202316239D0 (en) | 2023-10-24 | 2023-12-06 | Blue Earth Diagnostics Ltd | Therapeutic combination |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001346A1 (en) * | 1993-06-30 | 1995-01-12 | Akzo Nobel N.V. | Chelating compounds |
| CA2455598A1 (en) | 2001-07-27 | 2003-02-13 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| AU2015273934B2 (en) * | 2014-06-10 | 2020-08-20 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| WO2016062370A1 (en) | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20160287730A1 (en) * | 2015-03-31 | 2016-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Labeled evans blue dye derivative for in vivo serum albumin labeling |
| US10800797B2 (en) * | 2015-05-26 | 2020-10-13 | California Institute Of Technology | Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same |
| US11413360B2 (en) | 2017-07-28 | 2022-08-16 | Technische Universität München | Dual mode radiotracer and—therapeutics |
| WO2019115547A1 (en) * | 2017-12-11 | 2019-06-20 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| IL303420A (en) | 2019-01-30 | 2023-08-01 | Univ Muenchen Tech | Diagnostic imaging materials for cancer |
| AU2020213678B2 (en) | 2019-01-30 | 2024-05-30 | Technische Universität München | PSMA binding dual mode radiotracer and therapeutic |
-
2018
- 2018-07-30 US US16/634,759 patent/US11413360B2/en active Active
- 2018-07-30 PL PL18743540.9T patent/PL3658194T3/pl unknown
- 2018-07-30 MX MX2020000352A patent/MX2020000352A/es unknown
- 2018-07-30 IL IL318092A patent/IL318092A/en unknown
- 2018-07-30 WO PCT/EP2018/070533 patent/WO2019020831A1/en not_active Ceased
- 2018-07-30 EA EA202090370A patent/EA202090370A1/ru unknown
- 2018-07-30 SG SG11202000725WA patent/SG11202000725WA/en unknown
- 2018-07-30 IL IL272291A patent/IL272291B2/en unknown
- 2018-07-30 PT PT187435409T patent/PT3658194T/pt unknown
- 2018-07-30 ES ES18743540T patent/ES3011272T3/es active Active
- 2018-07-30 BR BR112020001785-0A patent/BR112020001785A2/pt unknown
- 2018-07-30 CN CN201880062949.0A patent/CN111132700B/zh active Active
- 2018-07-30 FI FIEP18743540.9T patent/FI3658194T3/fi active
- 2018-07-30 HU HUE18743540A patent/HUE070098T2/hu unknown
- 2018-07-30 JP JP2020526688A patent/JP7059372B2/ja active Active
- 2018-07-30 DK DK18743540.9T patent/DK3658194T3/da active
- 2018-07-30 EP EP18743540.9A patent/EP3658194B1/en active Active
- 2018-07-30 AU AU2018308699A patent/AU2018308699B2/en active Active
- 2018-07-30 EP EP24184312.7A patent/EP4424378A3/en active Pending
- 2018-07-30 EP EP22150556.3A patent/EP4000640A1/en not_active Withdrawn
- 2018-07-30 CA CA3071315A patent/CA3071315A1/en active Pending
- 2018-07-30 KR KR1020207005589A patent/KR102752620B1/ko active Active
- 2018-07-30 KR KR1020247006169A patent/KR20240027896A/ko not_active Ceased
-
2020
- 2020-01-10 MX MX2023007914A patent/MX2023007914A/es unknown
- 2020-01-23 ZA ZA2020/00467A patent/ZA202000467B/en unknown
-
2022
- 2022-04-12 JP JP2022065524A patent/JP2022101601A/ja active Pending
- 2022-06-24 US US17/849,297 patent/US12390540B2/en active Active
-
2024
- 2024-01-24 AU AU2024200440A patent/AU2024200440B2/en active Active
- 2024-11-15 US US18/948,808 patent/US12453787B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007914A (es) | Marcador radioactivo de modo dual y terapeuticos. | |
| MX2023006274A (es) | Agentes de imagenes de diagnostico del cancer. | |
| PH12020550898A1 (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| PH12018500285A1 (en) | Bridge linkers for conjugation of a cell-binding molecule | |
| MX2021013055A (es) | Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos. | |
| MX2022010703A (es) | Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores. | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| MA40074A (fr) | Composés liant ras multivalents | |
| NZ737471A (en) | Hydrophilic linkers for conjugation | |
| EP3533473A3 (en) | Compounds for positron emission tomography | |
| CO2017004471A2 (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| EA201490644A1 (ru) | Терапевтические пептиды | |
| EP4556029A3 (en) | Radiopharmaceutical conjugate | |
| NZ718826A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
| MX2021008999A (es) | Agentes radiotrazadores y agentes terapeuticos de modo doble, que se unen al antigeno de membrana especifico de la prostata. | |
| NZ710746A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| MX343405B (es) | Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando. | |
| MX2023007810A (es) | Compuestos de complejo de hierro para uso terapeutico. | |
| MX374535B (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico. | |
| BR112017022252A2 (pt) | conjugados de anticorpo-droga sítio-específicos | |
| MY209035A (en) | Tricyclic compounds and their use | |
| MX2020003089A (es) | Analogos de tailanstatina. | |
| ZA202101990B (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| JOP20170115B1 (ar) | مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3 |